Neuro-oncological Disorders in Women

  • Na Tosha N. GatsonEmail author
  • Erika N. Leese


Neuro-Oncology of Women (N.O.W.) is aimed to bring awareness to and increase research around pertinent neuro-oncology issues over the changing microenvironmental states over the female lifespan. Few neuro-oncologic diseases have validated clinical guidelines pertaining to pubescent, reproductive-aged, or peri/post-menopausal females. While some of the most common intracranial tumors predominantly affect women, guiding research on the use of hormone therapies, fertility, pregnancy, and tumor monitoring during pregnancy or perimenopausal stages are lacking. Questions about specialized tumor surveillance, pregnancy prevention/promotion, and fertility/pregnancy risks for tumor treating devices and immunotherapies are not confidently answered. As cancer therapies extend patient overall-survival, clinicians must be increasingly prepared to address brain tumors in women at various life-stages. Finally, the psycho-social impact on women and their families is discussed. Here, we feature neuro-oncology conditions in women and emphasize the common patient and clinician concerns.


Brain metastases Breast cancer Fertility Sex hormones Meningioma Paraneoplastic disease Pituitary tumors Pregnancy Neuro-Oncology of Women (N.O.W.) Women’s Neurology 


  1. 1.
    Murrell DH, Foster PJ. Brain metastasis: basic biology, clinical management, and insight from experimental model systems. In: Introduction to cancer metastasis. Aamir Ahmad. Elsevier UK. 2017. p. 317–333.CrossRefGoogle Scholar
  2. 2.
    Braganza MZ, Kitahara CM, Berrington de Gonzalez A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro-Oncology. 2012;14(11):1316–24.CrossRefGoogle Scholar
  3. 3.
    Turner MC. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother. 2012;61:1493–510.CrossRefGoogle Scholar
  4. 4.
    Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2009–2013. Neuro-Oncology. 2016;18(5):1–75.CrossRefGoogle Scholar
  5. 5.
    Schlehofer B, Blettner M, Wahrendorf J. Association between brain tumors and menopausal status. J Natl Cancer Inst. 1992;84(17):1346–9.CrossRefGoogle Scholar
  6. 6.
    Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7(4):279–87.PubMedGoogle Scholar
  7. 7.
    Simon RH. Brain tumors in pregnancy. Semin Neurol. 1988;8(3):214–21.CrossRefGoogle Scholar
  8. 8.
    Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA. 2016;316(9):952–61.CrossRefGoogle Scholar
  9. 9.
    Markwalder TM, Zara DT, Goldhirsch A, Markwalder RV. Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features. Surg Neurol. 1983;20:42–7.CrossRefGoogle Scholar
  10. 10.
    Black PM. Meningiomas. Neurosurgery. 1993;32:643–57.CrossRefGoogle Scholar
  11. 11.
    Chamberlain MC, Barnholtz JS. Medical treatment of recurrent meningiomas. Exp Rev Neurothera. 2014;11(10):1425–32.CrossRefGoogle Scholar
  12. 12.
    Carroll RS, Zhang J, Dashner K, Sar M, Wilson EM, Black PM. Androgen receptor expression in meningiomas. J Neurosurg. 1995;82:453–60.CrossRefGoogle Scholar
  13. 13.
    Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg. 2013;118(3):649–56.Google Scholar
  14. 14.
    Blitshteyn S, Cook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol. 2008;26(2):279–82.CrossRefGoogle Scholar
  15. 15.
    Qi Z, Shao C, Huang Y, Huo G, Zhou Y, Wang Z. Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS One. 2013;8(12):e83261.CrossRefGoogle Scholar
  16. 16.
    Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015;33(34):4093–8.CrossRefGoogle Scholar
  17. 17.
    Rubinstein AB, Loren D, Geier A, Reichenthal E, Gadoth N. Hormone receptors in initially excised versus recurrent intracranial meningiomas. J Neurosurg. 1994;81:184–7.CrossRefGoogle Scholar
  18. 18.
    Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, et al. Pregnancy and glial brain tumors. Neuro-Oncology. 2014;16(9):1289–94.CrossRefGoogle Scholar
  19. 19.
    Thapar K, Laws ER. Pituitary tumors. In: Kaye AH, Laws ER, editors. Brain tumors. New York: Churchill Livingstone; 1995. p. 759–76.Google Scholar
  20. 20.
    Randall RV, Laws ER, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW. Transphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc. 1983;58:108–21.PubMedGoogle Scholar
  21. 21.
    Swain SM. Triple-negative breast cancer: metastatic risk and role of platinum agents. Paper presented at: 44th Annual Meeting of the American Society of Clinical Oncology; May 30–June 3, 2008; Chicago.Google Scholar
  22. 22.
    Glick RP, Penny D, Hart A. The pre-operative and post-operative management of the brain tumor patient. In: Morantz RA, Walsh JW, editors. Brain tumors. New York: Marcel Dekker; 1994. p. 345–66.Google Scholar
  23. 23.
    Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470.CrossRefGoogle Scholar
  24. 24.
    Forsyth PJ, Cascino TL. Neurological complications of chemotherapy. In: Wiley RG, editor. Neurological complications of cancer. New York: Marcel Dekker; 1995. p. 241–66.Google Scholar
  25. 25.
    Posner JB. Neurologic complications of cancer. Philadelphia: F. A. Davis Company; 1995.Google Scholar
  26. 26.
    Graus F, Vega F, Delattre JY, Bonaventura I, Rene R, Arbaiza D, et al. Plasmapharesis and antineoplastic treatment in central nervous system paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992;42:536–40.CrossRefGoogle Scholar
  27. 27.
    OncLink. Men’s guide to sexuality during & after cancer treatment [Internet]. Philadelphia: The Abramson Cancer Center of the University of Pennsylvania. [updated 2017 June 20]. Available from:
  28. 28.
    Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6(247):247.CrossRefGoogle Scholar
  29. 29.
    Gao F, Cui Y, Jiang H, Dali S, Wang Y, Jiang Z, et al. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016;7(44):71330–40.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Khosrotehrani K, Johnson KL, Cha DH, Salomon RN, Bianchi DW. Transfer of fetal cells with multilineage potential to maternal tissue. JAMA. 2004;292(1):75–80.CrossRefGoogle Scholar
  31. 31.
    Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–43.CrossRefGoogle Scholar
  32. 32.
    Chan WN, Gurnot C, Montine TJ, Sonnen JA, Guthrie KA, Nelson JL. Male microchimerism in the human female brain. PLoS One. 2012;7(9):e45592.CrossRefGoogle Scholar
  33. 33.
    Carlson RH. Study: women with brain tumors have 10 times rate of divorce as men with brain tumors. Oncol Times. 2001;23(8):63.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Geisinger Neuroscience InstituteDanvilleUSA
  2. 2.Geisinger Cancer InstituteDanvilleUSA

Personalised recommendations